CBIO

CRESCENT BIOPHARMA INC.

CBIO·G2545C104·US·Common Stock·Healthcare - Biotechnology-Activist

CBIO (CRESCENT BIOPHARMA INC.) is held by 36 institutional investors as of Q1 2026. Largest holders: FMR LLC ($75.9M), BALYASNY ASSET MANAGEMENT L.P. ($27.7M), VANGUARD CAPITAL MANAGEMENT LLC ($14.7M). Net institutional sentiment: Bullish.

36
Holders
Avg rating(4 Elite)
$179.3M
Total Value
68% (43)
Fund Consensus
23 buying - 11 selling
CBIOSmart Money Verdict
View all
Held by 36 funds
4 elite
Who's Trading
InsiderBTBrumm Joshua TSell $761KJun 22, 2026
InsiderMJMcNeill JonathanSell $370KJun 22, 2026
InsiderPJPinkas JanSell $23KJun 22, 2026
InsiderIEIm Ellie EunkyungSell $22KJun 22, 2026
InsiderSWScalzo Richard WilliamSell $20KJun 22, 2026
InsiderBHBispham Barbara HarlinSell $22KJun 22, 2026
InsiderLRLynch RyanSell $8KJun 22, 2026
ActivistBalyasny Asset Management L.P.Balyasny Asset Management L.P.5.5%May 15, 2026
ActivistTATANG CAPITAL MANAGEMENT, LLC4.2%May 15, 2026
ActivistVHVenrock Healthcare Capital Partners III, L.P.9.5%Feb 17, 2026
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Unchanged
4.1M$75.9M0.0%+32.66%
0
Increased
1.5M(+1251.7%)$27.7M0.0%+54.54%
46
New
801,395$14.7M0.0%+54.96%
39
Unchanged
372,856$6.8M0.1%+49.48%
0
Increased
323,553(+422.9%)$5.9M0.0%+53.88%
44
Decreased
303,551(-10.2%)$5.6M0.0%+41.09%
0
Unchanged
300,000$5.5M0.0%+49.48%
0
Unchanged
264,000$4.8M0.0%+49.48%
0
Increased
228,475(+805.0%)$4.2M0.0%+53.30%
43
Increased
213,635(+274.5%)$3.9M0.0%+53.46%
43
Increased
200,780(+819.9%)$3.7M0.0%+53.32%
43
New
152,974$2.8M0.0%+54.96%
36
Decreased
115,828(-7.5%)$2.1M0.0%+47.50%
0
Increased
115,725(+6.0%)$2.1M0.0%+39.66%
19
Increased
104,221(+14.4%)$1.9M0.0%+44.43%
29
New
88,867$1.6M0.0%+54.96%
35
Increased
82,706(+1060.8%)$1.5M0.0%+53.58%
41
Unchanged
74,000$1.4M0.0%+49.48%
0
New
49,423$907,9010.0%+54.96%
34
Increased
39,067(+49.0%)$717,6610.0%+47.02%
23

Showing 1-20 of 43

1 / 3

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used